### cobas®

#### REF

09015060190

### 09015060500

i

#### English

#### System information

For **cobas e** 411 analyzer: test number 1810 For **cobas e** 601 and **cobas e** 602 analyzers: Application Code Number 134

#### Please note

The measured AFP value of a patient's sample can vary depending on the testing procedure used. The laboratory finding must therefore always contain a statement on the AFP assay method used. AFP values determined on patient samples by different testing procedures cannot be directly compared with one another and could be the cause of erroneous medical interpretations. If there is a change in the AFP assay procedure used while monitoring therapy, then the AFP values obtained upon changing over to the new procedure must be confirmed by parallel measurements with both methods.

#### Intended use

Immunoassay for the in vitro quantitative determination of  $\alpha_{1}\mbox{-fetoprotein}$  in human serum and plasma.

This assay is intended for the use as:

- An aid in the diagnosis of hepatocellular carcinoma (HCC).
- An aid in the management of patients with non-seminomatous germ cell tumors.
- One component in combination with other parameters to evaluate the risk of trisomy 21 (Down syndrome). Further testing is required for diagnosis of chromosomal aberrations.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on cobas e immunoassay analyzers.

#### Summary

Alpha1-fetoprotein (AFP), an albumin-like glycoprotein with a molecular weight of approximately 70 kDa, is formed in the yolk sac during fetal life, in non-differentiated liver cells, and the fetal gastro-intestinal tract.<sup>1,2</sup>

Tumors that synthesize AFP are mainly testicular non-seminomatous germ cell tumors (NSGCT), yolk sac tumors of the ovary and hepatocellular carcinoma (HCC). Moreover AFP is an important part in the risk assessment for trisomy 21 in the second trimester of pregnancy together with hCG+ $\beta$  and other parameters.<sup>3</sup>

#### Testicular cancer

Careful monitoring of the serum tumor markers AFP and human chorionic gonadotropin (hCG) is essential in the management of patients with germ cell tumors (GCT), as these markers are important for diagnosis, as prognostic indicators, in monitoring treatment response, and in the detection of early relapse.<sup>4</sup> In addition, hCG and AFP are important parameters for estimating the survival rate of patients with advanced NSGCTs and are also recommended by the National Academy of Clinical Biochemistry for the management of such patients.<sup>5</sup>

#### Hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is frequently the result of advanced liver disease and can develop in patients with and without cirrhosis.<sup>6</sup> AFP has long been recognized as a biomarker for HCC, and has played a prominent role in the diagnosis of HCC. Substantially elevated AFP values can indicate primary liver cell carcinoma and it has been shown that AFP levels increase with tumor size.<sup>7</sup> Diagnosis of HCC has primarily relied on the presence of typical features seen on contrast-enhanced imaging studies, histopathological assessment, and serum AFP levels.<sup>8</sup> While AFP is elevated during hepato-carcinogenesis, it can also be found in other tumors such as testicular, embryonic or gastric cancer.<sup>9,10</sup> AFP has reported sensitivities ranging from 39 to 65 %, and specificities from 76 to 94 % in HCC patients.<sup>11</sup> The divergence in sensitivity and specificity of AFP in these studies is probably due to a variety of factors including different etiologies, variable study designs, and different cutoff values. As the AFP values can

/	SYSTEM
	cobas e 411
	cobas e 601
	cobas e 602

also rise during regeneration of the liver, moderately elevated values are found in alcohol-mediated liver cirrhosis and acute viral hepatitis.<sup>12</sup> Surveillance of patients at risk for developing HCC by abdominal ultrasonography in combination with AFP is recommended by several clinical practice guidelines.<sup>13,14,15</sup>

#### Trisomy 21

100

Measurement of AFP makes a contribution to the risk assessment for trisomy 21 (Down syndrome) in the second trimester of pregnancy together with hCG+ $\beta$  and other parameters, such as exact gestational age and maternal weight.<sup>3</sup> In a trisomy 21 affected pregnancy the maternal serum concentration of AFP is decreased whereas the maternal serum hCG+ $\beta$  concentration is approximately twice the normal median.<sup>16</sup> The risk for a trisomy 21 affected pregnancy in the second trimester can be calculated by a suitable software (see "Materials required, but not provided" section) using the algorithm as described by Cuckle et al.<sup>17</sup> and the respective assay specific parameters.<sup>18,19,20,21,22</sup>

#### **Test principle**

Sandwich principle. Total duration of assay: 18 minutes.

- 1st incubation: 10 µL of sample, a biotinylated monoclonal AFP-specific antibody, and a monoclonal AFP-specific antibody labeled with a ruthenium complex<sup>a</sup>) react to form a sandwich complex.
- 2nd incubation: After addition of streptavidin-coated microparticles, the complex becomes bound to the solid phase via interaction of biotin and streptavidin.
- The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell/ProCell M. Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier.
- Results are determined via a calibration curve which is instrumentspecifically generated by 2-point calibration and a master curve provided via the reagent barcode or e-barcode.
- a) Tris(2,2'-bipyridyl)ruthenium(II)-complex (Ru(bpy)<sub>3</sub><sup>2+</sup>)

#### **Reagents - working solutions**

The reagent rackpack is labeled as AFP.

- M Streptavidin-coated microparticles (transparent cap), 1 bottle, 6.5 mL: Streptavidin-coated microparticles 0.72 mg/mL; preservative.
- R1 Anti-AFP-Ab~biotin (gray cap), 1 bottle, 10 mL:

Biotinylated monoclonal anti-AFP antibodies (mouse) 4.5 mg/L; phosphate buffer 100 mmol/L, pH 6.0; preservative.

R2 Anti-AFP-Ab~Ru(bpy)<sub>3</sub><sup>2+</sup> (black cap), 1 bottle, 10 mL:

Monoclonal anti-AFP antibodies (mouse) labeled with ruthenium complex 12.0 mg/L; phosphate buffer 100 mmol/L, pH 6.0; preservative.

#### Precautions and warnings

For in vitro diagnostic use for health care professionals. Exercise the normal precautions required for handling all laboratory reagents. Infectious or microbial waste:

Warning: handle waste as potentially biohazardous material. Dispose of waste according to accepted laboratory instructions and procedures. Environmental hazards:

Apply all relevant local disposal regulations to determine the safe disposal. Safety data sheet available for professional user on request.

This kit contains components classified as follows in accordance with the Regulation (EC) No. 1272/2008:





#### Warning

H317	May cause an allergic skin reaction.
H412 Prevention:	Harmful to aquatic life with long lasting effects.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P273	Avoid release to the environment.
P280	Wear protective gloves.
Response:	
P333 + P313	If skin irritation or rash occurs: Get medical advice/attention.

P362 + P364 Take off contaminated clothing and wash it before reuse.

#### Disposal:

P501 Dispose of contents/container to an approved waste disposal plant.

Product safety labeling follows EU GHS guidance.

Contact phone: all countries: +49-621-7590

Avoid foam formation in all reagents and sample types (specimens, calibrators and controls).

#### **Reagent handling**

The reagents in the kit have been assembled into a ready-for-use unit that cannot be separated.

All information required for correct operation is read in from the respective reagent barcodes.

#### Storage and stability

Store at 2-8 °C.

Do not freeze.

Store the Elecsys reagent kit **upright** in order to ensure complete availability of the microparticles during automatic mixing prior to use.

Stability:

unopened at 2-8 °C	up to the stated expiration date
after opening at 2-8 °C	12 weeks
on cobas e 411 and cobas e 601	8 weeks
on <b>cobas e</b> 602	4 weeks

#### Specimen collection and preparation

Only the specimens listed below were tested and found acceptable. Serum collected using standard sampling tubes or tubes containing separating gel.

Li-heparin, K<sub>2</sub>-EDTA and K<sub>3</sub>-EDTA plasma.

Plasma tubes containing separating gel can be used.

Criterion: Slope 0.9-1.1 + coefficient of correlation  $\ge$  0.95.

Stable for 5 days at 20-25 °C, 14 days at 2-8 °C, 6 months at

-20 °C (± 5 °C). The samples may be frozen 3 times.

The suitability of plasma samples for estimating the risk of trisomy 21 has not been evaluated.

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer. Centrifuge samples containing precipitates before performing the assay. Do not use heat-inactivated samples.

Do not use samples and controls stabilized with azide.

Ensure the samples, calibrators and controls are at 20-25  $^{\circ}\mathrm{C}$  prior to measurement.

Due to possible evaporation effects, samples, calibrators and controls on the analyzers should be analyzed/measured within 2 hours.

#### Materials provided

See "Reagents - working solutions" section for reagents.

#### Materials required (but not provided)

- REF 09227261190, AFP CalSet II, for 4 x 1.0 mL
- REF 11776452122, PreciControl Tumor Marker, for 4 x 3.0 mL or
  REF 11731416190, PreciControl Universal, for 4 x 3.0 mL or
  REF 08754551190, PreciControl HCC V2, for 4 x 1.0 mL
- REF 05192943190, Diluent Universal 2, 2 x 36 mL sample diluent
- General laboratory equipment
- cobas e analyzer

For risk calculation of trisomy 21:

- A suitable software, e.g.
  REF 05126193, SsdwLab (V5.0 or later), single user licence
  REF 05195047, SsdwLab (V5.0 or later), multi user licence
- REF 03271749190, Elecsys HCG+β, 100 tests
- REF 03302652190, HCG+β CalSet, for 4 x 1 mL

Additional materials for the cobas e 411 analyzer:

- REF 11662988122, ProCell, 6 x 380 mL system buffer
- REF 11662970122, CleanCell, 6 x 380 mL measuring cell cleaning solution
- REF 11930346122, Elecsys SysWash, 1 x 500 mL washwater additive
- REF 11933159001, Adapter for SysClean
- REF 11706802001, AssayCup, 60 x 60 reaction cups
- REF 11706799001, AssayTip, 30 x 120 pipette tips
- REF 11800507001, Clean-Liner

Additional materials for cobas e 601 and cobas e 602 analyzers:

- REF 04880340190, ProCell M, 2 x 2 L system buffer
- REF 04880293190, CleanCell M, 2 x 2 L measuring cell cleaning solution
- REF 03023141001, PC/CC-Cups, 12 cups to prewarm ProCell M and CleanCell M before use
- REF 03005712190, ProbeWash M, 12 x 70 mL cleaning solution for run finalization and rinsing during reagent change
- REF 12102137001, AssayTip/AssayCup, 48 magazines x 84 reaction cups or pipette tips, waste bags
- REF 03023150001, WasteLiner, waste bags
- REF 03027651001, SysClean Adapter M

Additional materials for all analyzers:

 REF 11298500316, ISE Cleaning Solution/Elecsys SysClean, 5 x 100 mL system cleaning solution

#### Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

Resuspension of the microparticles takes place automatically prior to use. Read in the test-specific parameters via the reagent barcode. If in exceptional cases the barcode cannot be read, enter the 15-digit sequence of numbers.

Bring the cooled reagents to approximately 20 °C and place on the reagent disk (20 °C) of the analyzer. Avoid foam formation. The system automatically regulates the temperature of the reagents and the opening/closing of the bottles.

### cobas®

#### Calibration

Traceability: This method has been standardized against the 1st IRP WHO Reference Standard 72/225.

Every Elecsys reagent set has a barcoded label containing specific information for calibration of the particular reagent lot. The predefined master curve is adapted to the analyzer using the relevant CalSet.

*Calibration frequency:* Calibration must be performed once per reagent lot using fresh reagent (i.e. not more than 24 hours since the reagent kit was registered on the analyzer).

Calibration interval may be extended based on acceptable verification of calibration by the laboratory.

Renewed calibration is recommended as follows:

- after 1 month (28 days) when using the same reagent lot
- after 7 days (when using the same reagent kit on the analyzer)
- as required: e.g. quality control findings outside the defined limits

#### Quality control

T

For quality control, use PreciControl Tumor Marker or PreciControl Universal or PreciControl HCC V2.

In addition, other suitable control material can be used.

Controls for the various concentration ranges should be run individually at least once every 24 hours when the test is in use, once per reagent kit, and following each calibration.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

If necessary, repeat the measurement of the samples concerned.

Follow the applicable government regulations and local guidelines for quality control.

#### Calculation

The analyzer automatically calculates the analyte concentration of each sample either in IU/mL, ng/mL, kIU/L or additionally in IU/L with **cobas e** 601 and **cobas e** 602 analyzers.

Conversion factors:	IU/mL x 1.21 = ng/mL
	ng/mL x 0.83 = IU/mL

#### Limitations - interference

The effect of the following endogenous substances and pharmaceutical compounds on assay performance was tested. Interferences were tested up to the listed concentrations and no impact on results was observed.

#### Endogenous substances

Compound	Concentration tested
Bilirubin	$\leq$ 1112 µmol/L or $\leq$ 65 mg/dL
Hemoglobin	$\leq$ 1.37 mmol/L or $\leq$ 2200 mg/dL
Intralipid	≤ 1500 mg/dL
Biotin	≤ 4912 nmol/L or ≤ 1200 ng/mL
Rheumatoid factors	≤ 1500 IU/mL

Criterion: Recovery of  $\pm$  0.4 IU/mL of initial value for samples  $\leq$  4 IU/mL, within  $\pm$  10 % of initial value for samples > 4 IU/mL.

There is no high-dose hook effect at AFP concentrations up to 1 million IU/mL (1.21 million ng/mL).

In vitro tests were performed on 26 commonly used pharmaceuticals. No interference with the assay was found.

In rare cases, interference due to extremely high titers of antibodies to analyte-specific antibodies, streptavidin or ruthenium can occur. These effects are minimized by suitable test design.

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

#### Limits and ranges

#### Measuring range

0.75-1000 IU/mL or 0.908-1210 ng/mL (defined by the Limit of Blank and the maximum of the master curve). Values below the Limit of Blank are reported as < 0.75 IU/mL or < 0.908 ng/mL. Values above the measuring range are reported as > 1000 IU/mL or > 1210 ng/mL (or up to 50000 IU/mL or 60500 ng/mL for 50-fold diluted samples).

#### Lower limits of measurement

Limit of Blank, Limit of Detection and Limit of Quantitation

Limit of Blank = 0.75 IU/mL (or 0.91 ng/mL)

Limit of Detection = 1.5 IU/mL (or 1.82 ng/mL)

Limit of Quantitation = 2.25 IU/mL (or 2.72 ng/mL)

The Limit of Blank, Limit of Detection and Limit of Quantitation were determined in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP17-A2 requirements.

The Limit of Blank is the 95<sup>th</sup> percentile value from n  $\ge$  60 measurements of analyte-free samples over several independent series. The Limit of Blank corresponds to the concentration below which analyte-free samples are found with a probability of 95 %.

The Limit of Detection is determined based on the Limit of Blank and the standard deviation of low concentration samples. The Limit of Detection corresponds to the lowest analyte concentration which can be detected (value above the Limit of Blank with a probability of 95 %).

The Limit of Quantitation is the lowest analyte concentration that can be reproducibly measured with an intermediate precision CV of  $\leq$  20 %.

#### Dilution

Samples with AFP concentrations above the measuring range can be diluted with Diluent Universal 2. The recommended dilution is 1:50 (either automatically by the analyzers or manually). The concentration of the diluted sample must be > 18 IU/mL (> 21.8 ng/mL).

After manual dilution, multiply the result by the dilution factor.

After dilution by the analyzers, the software automatically takes the dilution into account when calculating the sample concentration.

#### Expected values

Results of following studies using the Elecsys AFP assay see below:

a) Multicenter study "Elecsys 2010 analyzer" status September 1997 and reference range study in Germany and France, data evaluated in September 1998.

Following AFP values were found in serum samples from 646 healthy test subjects:

 $\leq$  5.8 IU/mL or  $\leq$  7.0 ng/mL for 95 % of the results.

AFP median values for completed weeks of pregnancy (defined as completed weeks of pregnancy beginning with the start of the last menstruation phase):

Weeks	14	15	16	17	18	19
N	382	1782	2386	975	353	146
IU/mL	23.2	25.6	30.0	33.5	40.1	45.5
ng/mL	27.9	30.9	36.1	40.4	48.3	54.8

b) Multicenter study to determine reference values for evaluating the risk of trisomy 21 in maternal serum (study No. BO1P019).

Values from serum samples of 1753 pregnant women in total (relevant gestational weeks 14 to 18) were evaluated.

Measurements with the Elecsys HCG+ $\beta$  assay and the Elecsys AFP assay were conducted in 5 clinical centers in Belgium, France, and Germany.

The gestational age in days determined by ultrasound was given for each sample. From a log-linear regression analysis of all 1753 AFP values versus gestational age the following median values were calculated for the middle of the respective weeks (e.g. week 14 + 3 days):

Weeks	14	15	16	17	18
IU/mL	20.9	24.0	27.6	31.7	36.4
ng/mL	25.3	29.0	33.3	38.3	44.0

*Note:* For prenatal testing it is recommended that the median values be reevaluated periodically (1 to 3 years) and whenever methodology changes. The transferability of the reference values to plasma samples has not been verified.

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

#### Elecsys AFP as an aid in the diagnosis of HCC

A prospective multicenter study (Roche study No. RD002542 and RD002543) to evaluate the clinical performance of Elecsys AFP as an aid in the diagnosis of HCC included 376 patients with liver disease, of which 168 had HCC and 208 had liver disease but no diagnosis of HCC (control).

	Median age	Gender (% male)	Race				
			Asian	Caucasian	Black	Other	Missing
			(%)	(%)	(%)	(%)	(%)
Control	53	60.6	47.6	48.6	1.4	0	2.4
HCC	64	83.9	42.3	56.5	0	0.6	0.6


#### a) Range of AFP concentration in HCC cases compared to controls

The following table and graph show the range of AFP concentration in samples from HCC patients staged according to Barcelona clinic liver cancer classification (BCLC)<sup>23</sup> compared to controls. For the 168 patients with a diagnosis of HCC, the AFP concentration increased with disease progression, especially in late stage disease. All concentrations in the table are in IU/mL and (ng/mL), while concentrations in the graph are in IU/mL. The thick line in the box plots represents the median value.

Disease stage	N	Min/Max	Mean	Median	25 <sup>th</sup> -75 <sup>th</sup> perc. <sup>b)</sup>
			± SD		
Control <sup>C)</sup>	208	0.85/327.84	5.33±23.15	2.42	1.86-3.89
		(1.03/396.69)	(6.45±28.01)	(2.92)	(2.25-4.71)
Early (Stage 0 + A)	77	1.04/5224	252±799	9.7	3.72-39.6
		(1.26/6322)	(305±966)	(11.7)	(4.5-47.9)
BCLC Stage 0	10	1.04/258	58.4±98.9	9.67	-
		(1.26/312)	(70.7±120)	(11.7)	
BCLC Stage A	67	1.48/5224	281±852	9.7	3.72-39.6
		(1.79/6322)	(340±1031)	(11.7)	(4.5-47.9)
Late (Stages B, C and D)	91	1.3/44687	2874±8259	119	5.95-909
		(1.57/54071)	(3478±9994)	(144)	(7.2-1100)
BCLC Stage B	26	2.85/34944	1989±7301	15.5	5.33-132
		(3.45/42282)	(2407±8834)	(18.8)	(6.45-160)
BCLC Stage C	57	1.3/44687	2313±7079)	150	6.14-959
		(1.57/54071)	(2798±8566)	(182)	(7.43-1160)
BCLC Stage D	8	557/34531	9751±15043	999	-
		(674/41782)	(11799±18201)	(1209)	

b) not calculated if sample size is 20 or below

c) In the graphical representation below, this group is designated with an "X"



cobas®

x ---> X: Control; O: Stage 0; A: Stage A; B: Stage B; C: Stage C; D: Stage D

y ---> ĂFP (IU/mL)

#### b) AFP concentration and disease etiology


The AFP concentration as function of etiology for the two patient groups (Control, 1-A to 1-F and HCC, 2-A to 2F) is shown in the following table and graph. All concentrations in the table are in IU/mL and (ng/mL), while concentrations in the graph are in IU/mL. The thick line in the box plots represents the median value.

Label	Etiology <sup>d)</sup>	N	Min/Max	Mean ±SD	Median	25 <sup>th</sup> -75 <sup>th</sup>
						perc.
1-A	Cirrhosis	79	0.851/66.9	4.92±8.59	2.63	1.85-4.34
			(1.03/80.9)	(5.95±10.4)	(3.19)	(2.24-5.25)
1-B	Hepatitis B	72	1.03/328	7.4±38.3	2.31	1.73-3.11
			(1.25/397)	(8.95±46.4)	(2.79)	(2.1-3.76)
1-C	Hepatitis C	27	1.3/6.33	3.23±1.43	2.49	2.21-4.73
			(1.57/7.66)	(3.9±1.73)	(3.01)	(2.67-5.73)
1-D	NASH <sup>e)</sup>	30	1.01/10.9	3.36±2.36	2.48	1.74-3.96
	N/IOI		(1.22/13.2)	(4.06±2.86)	(3.00)	(2.11-4.79)
1-E	ALD <sup>f)</sup>	0	-	-	-	•
1-F	Others	0	-	-	-	-
2-A	Cirrhosis	139	1.04/44687	1536±6096	16.6	4.82-320
			(1.26/54071)	(1859±7377)	(20.1)	(5.84-387)
2-B	Hepatitis B	14	2.25/1711	296±536	38.2	-
			(2.73/2070)	(358±649)	(46.2)	
2-C	Hepatitis C	3	1.86/999	348±564	43.1	-
			(2.25/1209)	(421±683)	(52.1)	
2-D	NASH	1	-	3.55 (4.3)		-
2-E	ALD	2	3.87/33288	16646±23535	16646	-
			(4.69/40278)	(20141±28478)	(20141)	
2-F	Others	9	1.98/16115	3216±5924	210	-
			(2.4/19499)	(3891±7168)	(254)	

d) All etiologies except cirrhosis are non-cirrhotic

e) Non-alcoholic steatohepatitis

f) Alcoholic liver disease



#### y ---> AFP (IU/mL)

c) Clinical performance of the Elecsys AFP assay in detecting HCC

The sensitivity and specificity of the Elecsys AFP assay in detecting HCC at a cut-off of 165 IU/mL (200 ng/mL) and 16.5 IU/mL (20 ng/mL), and the results of the Receiver Operating Characteristics (ROC) analysis are shown below.

		All HCC	Early Stage HCC <sup>g)</sup>	Late Stage HCC <sup>h)</sup>
AFP	Sensitvity	31.5 %	15.6 %	45.1 %
cut-off 200 ng/mL	(95 % CI) <sup>İ)</sup>	(24.6 %, 39.2 %)	(8.3 %, 25.6 %)	(34.6 %, 55.8 %)
	Specificity		99.5 %	
	(95 % CI)		(97.4 %, 100 %)	

		All HCC	Early Stage HCC <sup>g)</sup>	Late Stage HCC <sup>h)</sup>	
AFP	Sensitvity	51.8 %	36.4 %	64.8 %	
cut-off 20 ng/mL	(95 % CI)	(44 %, 59.5 %)	(25.7 %, 48.1 %)	(54.1 %, 74.6 %)	
	Specificity	98.1 %			
	(95 % CI)	(95.1 %, 99.5 %)			
ROC AUC <sup>j)</sup>		88 %	84.5 %	90.9 %	
100	//00	(84.5 %, 91.5 %)	(79.3 %, 89.7 %)	(86.8 %, 95.1 %)	

g) BCLC stages 0, A

h) BCLC stages B,C,D

i) Confidence interval

j) Area under the Curve

#### d) AFP values in different types of benign and malignant disorders

The following table and graph show the AFP concentration in IU/mL and (ng/mL) in a panel of samples from patients with either a benign liver disease, an immune disorder, or a malignancy other than HCC (N total 397; median age 54 years, 58 % female, 39 % Asian and 61 % Caucasian).

Label	Etiology	N	Min/Max	Mean	Median	25 <sup>th</sup> -75 <sup>th</sup>
				± (SD)		perc.
А	Benign liver	87	0.843/999	14.3±107	2.20	1.73-3.48
	diseases <sup>k</sup> )		(1.02/1209)	(17.3±129)	(2.66)	(2.10-4.21)
В	Rheumatoid arthritis	38	1.11/11.7	2.80±1.84	2.28	1.77-2.99
			(1.34/14.2)	(3.39±2.22)	(2.75)	(2.14-3.62)
С	Crohn's disease	37	0.676/10.0	3.21±2.40	2.42	1.63-3.58
			(0.819/12.1)	(3.88±2.90)	(2.93)	(1.97-4.34)
D	Ulcerative colitis	30	1.20/7.27	2.58±1.35	2.37	1.63-2.94
			(1.45/8.80)	(3.12±1.63)	(2.86)	(1.97-3.56)
Е	Other autoimmune	26	0.909/7.93	3.16±1.72	2.62	2.02-3.97
	diseases <sup>I)</sup>		(1.10/9.60)	(3.83±2.08)	(3.16)	(2.44-4.80)
F	Lung cancer	24	1.01/5.18	2.50±0.978	2.40	1.90-3.03
			(1.22/6.27)	(3.02±1.18)	(2.90)	(2.30-3.67)
G	Breast cancer	27	0.859/7.67	3.06±1.60	2.59	1.85-4.01
			(1.04/9.27)	(3.70±1.93)	(3.13)	(2.24-4.85)
Н	Renal cancer	10	0.58/6.43	2.73±1.96	2.21	-
			(0.702/7.78)	(3.30±2.37)	(2.67)	
Ι	Cholangio	27	1.06/83.8	7.48±15.9	3.51	2.15-4.82
	carcinoma		(1.28/101)	(9.05±19.3)	(4.25)	(2.60-5.84)
J	Pancreatic cancer	10	1.03/6.65	2.83±2.02	1.92	-
			(1.25/8.05)	(3.43±2.45)	(2.32)	
К	Other gastrointestin-	55	0.512/13.1	3.00±1.95	2.68	2.02-3.43
	al cancers <sup>m)</sup>		(0.62/15.9)	(3.63±2.35)	(3.24)	(2.44-4.15)
L	Gynecological	26	0.999/9.19	3.24±2.02	2.62	1.86-3.96
	n) cancers		(1.21/11.1)	(3.92±2.44)	(3.16)	(2.25-4.79)

k) polycystic liver disease, simple cysts, focal nodular hyperplasia, hemangioma, hepatocellular adenoma, non-cirrhotic alcohol liver disease

I) systemic lupus erythematosus, autoimmune thyroiditis

m) colorectal, gastric and esophageal cancer

n) ovarian, endometrial and cervical cancer

#### 

y ---> AFP (ng/mL)

#### Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

#### Precision

Precision was determined using Elecsys reagents, pooled human sera and controls in a protocol (EP05-A3) of the CLSI (Clinical and Laboratory Standards Institute): 2 runs per day in duplicate each for 21 days (n = 84). The following results were obtained:

cobas e 411 analyzer								
	Rep	peatabili				ermediate recision		
Sample	Mean		SD		CV	SD		CV
	IU/mL	ng/mL	IU/mL	ng/mL	%	IU/mL	ng/mL	%
HS <sup>o)</sup> 1	1.61	1.95	0.097	0.117	6.0	0.131	0.159	8.1
HS 2	2.14	2.59	0.074	0.090	3.5	0.160	0.194	7.5
HS 3	5.29	6.40	0.161	0.195	3.0	0.287	0.347	5.4
HS 4	16.1	19.5	0.441	0.534	2.7	0.864	1.05	5.4
HS 5	160	194	4.18	5.06	2.6	7.83	9.47	4.9
HS 6	460	557	12.2	14.8	2.7	22.3	27.0	4.8
HS 7	943	1141	20.9	25.3	2.2	48.4	58.6	5.1
PC TM <sup>p)</sup> 1	7.45	9.01	0.162	0.196	2.2	0.391	0.473	5.2
PC TM2	71.2	86.2	1.98	2.40	2.8	3.86	4.67	5.4
PC Uq)1	10.4	12.6	0.200	0.242	1.9	0.527	0.638	5.1
PC U 2	51.0	61.7	1.07	1.29	2.1	2.68	3.24	5.3
PC 1 HCC V2 <sup>r)</sup>	3.20	3.87	0.096	0.116	3.0	0.185	0.224	5.8
PC 2 HCC V2 <sup>s)</sup>	78.0	94.4	1.15	1.39	1.5	3.15	3.81	4.0

o) HS = human serum

p) PC TM = PreciControl Tumor Marker

q) PC U = PreciControl Universal

r) PC 1 HCC V2 = PreciControl HCC V2, Level 1

s) PC 2 HCC V2 = PreciControl HCC V2, Level 2

cobas e 601 and cobas e 602 analyzers								
Repeatability							termediate precision	
Sample	Me	ean	S	SD CV		SD		CV
	IU/mL	ng/mL	IU/mL	ng/mL	%	IU/mL	ng/mL	%
HS <sup>o)</sup> 1	2.15	2.60	0.054	0.065	2.5	0.080	0.097	3.7
HS 2	1.72	2.08	0.051	0.062	3.0	0.073	0.088	4.2

cobas®

cobas e 601 and cobas e 602 analyzers								
	Rep	peatabili	ty	Intermediate precision				
Sample	Mean		SD C		CV	SD		CV
	IU/mL	ng/mL	IU/mL	ng/mL	%	IU/mL	ng/mL	%
HS 3	5.31	6.43	0.145	0.175	2.7	0.185	0.224	3.5
HS 4	16.0	19.4	0.500	0.605	3.1	0.618	0.748	3.9
HS 5	157	190	4.58	5.54	2.9	5.61	6.79	3.6
HS 6	515	623	15.4	18.6	3.0	19.6	23.7	3.8
HS 7	923	1117	29.1	35.2	3.2	36.2	43.8	3.9
PC TM <sup>p)</sup> 1	7.50	9.08	0.164	0.198	2.2	0.255	0.309	3.4
PC TM2	70.9	85.8	1.31	1.59	1.9	2.45	2.96	3.5
PC U <sup>q)</sup> 1	10.7	12.9	0.254	0.307	2.4	0.406	0.491	3.8
PC U 2	52.2	63.2	1.12	1.36	2.1	1.89	2.29	3.6
PC 1 HCC V2	3.10	3.75	0.113	0.137	3.7	0.195	0.236	6.3
PC 2 HCC V2	74.0	89.5	1.49	1.80	2.0	3.21	3.88	4.3

#### Method comparison

A comparison of the Elecsys AFP assay,  $\ensuremath{\mathbb{REF}}$  09015086190 (cobas e 601 analyzer; y) with the Elecsys AFP assay,  $\ensuremath{\mathbb{REF}}$  04481798190 (cobas e 601 analyzer; x) gave the following correlations (IU/mL):

Number of serum samples measured: 184

Passing/Bablok <sup>24</sup>	Linear regression		
y = 0.965 + 0.100	y = 0.969x - 0.143		
т = 0.985	r = 0.999		

The sample concentrations were between 1.1 and 966 IU/mL.

#### References

- Taketa K. Alpha-Fetoprotein in the 1990s. In: Sell SS. Serological cancer markers. Humana Press 1992;31-46, ISBN: 0-89603-209-4
- 2 Terentiev AA., Moldogazieva NT. Alpha-fetoprotein: a renaissance. Tumor Biology 2013;34:2075-2091.
- 3 Wald NJ, Kennard A, Densem JW, et al. Antenatal maternal serum screening for Down's syndrome: results of a demonstration project. BMJ 1992;305:391-394.
- 4 Klepp O. Serum tumor markers in testicular and extragonadal germ cell malignancies. Scand J Clin Lab Invest Suppl 1991;206:28-41.
- 5 Sturgeon CM, Duffy MJ, Stenman UH, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers. Clin Chem 2008;54:12:e11-e79.
- 6 Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nature Reviews Disease Primers. 2016;14:2:16018.
- 7 Toro A, Ardiri A, Mannino M, et al. Effect of pre- and post-treatment alpha-fetoprotein levels and tumor size on survival of patients with hepatocellular carcinoma treated by resection, transarterial chemoembolization or radiofrequency ablation: a retrospective study. BMC surgery 2014;14:40.
- 8 Gonzalez SA and Keeffe EB. Diagnosis of Hepatocellular Carcinoma: Role of Tumor Markers and Liver Biopsy. Clin Liver Dis 2011;15:297-306.
- 9 Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann. Intern. Med. 2003;139(1):46-50.
- 10 Chen J, Röcken C, Treiber G, et al. Clinical implications of alphafetoprotein expression in gastric adenocarcinoma. Dig Dis 2003;21(4):357-362.

11 Daniele B, Bencivenga A, Megna AS, et al. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004;127:108-112.

- 12 Stuart KE, Anand AJ, Jenkins RL. Hepatocellular Carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer 1996;77,11:2217-2222.
- 13 Heimbach JK, Kulik LM, Finn RS, et al. AASLD Guidelines for the Treatment of Hepatocellular Carcinoma. Hepatology 2018;67(1):358-80.
- 14 Kokudo N, Hasegawa K, Akahane M, et al. Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res 2015; 45:123-127.
- 15 Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017;11:317-370.
- 16 Schlebusch H. Prenatal screening for Down's syndrome. In: Thomas L (ed.). Clinical Laboratory Diagnosis, TH-Books, Frankfurt, 1st English edition 1998:1124-1125.
- 17 Cuckle HS, Wald NJ, Thompson SG. Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol 1987;94:387-402.
- 18 Reynolds TM, Penney MD. The mathematical basis of multivariate risk screening: with special reference to screening for Down's syndrome associated pregnancy. Ann Clin Biochem 1989;26:452-458.
- 19 Cuckle HS, Wald NJ, Nanchahal K, et al. Repeat maternal serum alpha-fetoprotein testing in antenatal screening programmes for Down's syndrome. Br J Obstet Gynaecol 1989;96:52-60.
- 20 Dunstan FDJ, Gray JC, Nix ABJ, et al. Detection rates and false positive rates for Down's Syndrome screening: How precisely can they be Estimated and what factors influence their value? Statistics Medicine 1997;16:1481-1495.
- 21 Lamson SH, Hook B. Comparison of Mathematical Models for the Maternal Age Dependence of Down's Syndrome Rates. Hum Genet Vol 1981;59:232-234.
- 22 Cuckle HS. Improved parameters for risk estimation in Down's syndrome screening. Prenat Diagn 1995;15:1057-1065.
- 23 Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19(3):329-338.
- 24 Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. J Clin Chem Clin Biochem 1988 Nov;26(11):783-790.

For further information, please refer to the appropriate operator's manual for the analyzer concerned, the respective application sheets and the Method Sheets of all necessary components (if available in your country).

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

Any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the Member State in which the user and/or the patient is established.

The Summary of Safety & Performance Report can be found here: https://ec.europa.eu/tools/eudamed

#### Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard (for USA: see dialog.roche.com for definition of symbols used):

CONTENT	Contents of kit
SYSTEM	Analyzers/Instruments on which reagents can be used
REAGENT	Reagent
CALIBRATOR	Calibrator
$\rightarrow$	Volume for reconstitution

6/7



### cobas®

GTIN

#### Global Trade Item Number

COBAS, COBAS E, ELECSYS and PRECICONTROL are trademarks of Roche. INTRALIPID is a trademark of Fresenius Kabi AB.

All other product names and trademarks are the property of their respective owners.

Additions, deletions or changes are indicated by a change bar in the margin. @ 2022, Roche Diagnostics



-

Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim www.roche.com

+800 5505 6606

